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he American College of Cardiology/American Heart Asso-
iation (ACC/AHA) Task Force on Practice Guidelines
akes every effort to avoid any actual, potential, or perceived
onflict of interest that might arise as a result of an industry
elationship or personal interest of the writing committee.
pecifically, all members of the writing committee, as well as
eer reviewers of the document, were asked to provide disclo-
ure statements of all such relationships that might be per-
eived as real or potential conflicts of interest. These statements
re reviewed by the parent task force, reported orally to all
embers of the writing committee at each meeting, and
pdated and reviewed by the writing committee as changes
ccur. Please see Appendix 1 for author relationships with
ndustry and Appendix 2 for peer reviewer relationships with
ndustry.
These guidelines attempt to define practices that meet the
eeds of most patients in most circumstances. These guideline
ecommendations reflect a consensus of expert opinion after a
horough review of the available, current scientific evidence and
re intended to improve patient care. If these guidelines are
sed as the basis for regulatory/payer decisions, the ultimate
oal is quality of care and serving the patient’s best interests.
he ultimate judgment regarding care of a particular patient
ust be made by the healthcare provider and patient in light of
ll the circumstances presented by that patient.
idney C. Smith Jr., MD, FACC, FAHA
hair, ACC/AHA Task Force on Practice Guidelines
lliot M. Antman, MD, FACC, FAHA
mmediate Past-Chair, ACC/AHA Task Force on
ractice Guidelines
. INTRODUCTION
.1. Purpose of the Expedited Update
ince the publication of the previous guidelines on periopera-
ive cardiovascular evaluation for noncardiac surgery in 2002,
he issue of perioperative beta blockade for non-cardiac surgery
as taken on increased importance. Specifically, the Physicians
onsortium for Performance Improvement and the Surgical
are Improvement Project have both identified perioperative
eta blockade as a quality measure. Given the importance of
hese quality measures for both public reporting and eventual
ay-for-performance, and the recent series of publications on
he subject, it became imperative to update the recommenda-
ions related to beta blockade. Therefore, we have chosen to
xpedite the review of the literature on perioperative beta
lockade in order to produce recommendations that can be
sed in these national quality initiatives. In general, ACC/
HA Class I and III indications for therapy identify potential
imensions of care and processes for performance measure-
ent; however, not all Class I and III guidelines recommen-ations should be selected for performance measurement (1).urthermore, Class IIa and Class IIb recommendations are not
onsidered for stand-alone measures.
Please note that the full 2002 Guideline on Perioperative
ardiovascular Evaluation for Noncardiac Surgery is being
pdated and represents current ACC/AHA policy, with the
xception of the text and tables in the perioperative beta-
locker therapy section. This focused update replaces the
eta-blocker section in the 2002 Guideline and is consid-
red current ACC/AHA policy until the update of the full
uideline is published. Please note that Table 2, “Clinical
redictors of Increased Perioperative Cardiovascular Risk,”
s currently under review and may be modified as part of the
pdate of the full guideline.
.2. Organization of Committee and Evidence Review
he Committee to Update the 2002 Guidelines on Perioper-
tive Cardiovascular Evaluation for Noncardiac Surgery: Fo-
used Update on Perioperative Beta-Blocker Therapy reviewed
he literature relevant to perioperative cardiac evaluation since
he last publication of these guidelines in 2002. Literature
earches were conducted in PubMed/MEDLINE. Searches
ere limited to the English language, 2002 through 2006, and
uman subjects. In addition, related-article searches were
onducted in MEDLINE to find further relevant articles.
inally, committee members recommended applicable articles
utside the scope of the formal searches.
As a result of these searches, 23 published articles and 1
bstract were identified and reviewed by the committee for
he expedited update of the Beta-Blocker section. Using
vidence-based methodologies developed by the ACC/
HA Task Force on Practice Guidelines, the committee
pdated the guideline text and recommendations.
These classes summarize the recommendations for pro-
edures or treatments as follows:
Class I: Conditions for which there is evidence for
and/or general agreement that the procedure or treat-
ment is beneficial, useful, and effective.
Class II: Conditions for which there is conflicting
evidence and/or a divergence of opinion about the
usefulness/efficacy of a procedure or treatment.
Class IIa: Weight of evidence/opinion is in favor of
usefulness/efficacy.
Class IIb: Usefulness/efficacy is less well established by
evidence/opinion.
Class III: Conditions for which there is evidence and/or
general agreement that the procedure/treatment is not
useful/effective, and in some cases may be harmful.
n addition, the weight of evidence in support of the
ecommendation is listed as follows:
Level of Evidence A: Data derived from multiple,
randomized, clinical trials.
Level of Evidence B: Data derived from a single-
randomized trial or non-randomized studies.
2345JACC Vol. 47, No. 11, 2006 Fleisher et al.
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case studies, or standard-of-care.
A recommendation with Level of Evidence B or C does not
mply that the recommendation is weak. Many important
linical questions addressed in guidelines do not lend them-
elves to clinical trials. Although randomized trials are not
vailable, there may be a very clear clinical consensus that a
articular test or therapy is useful and effective. The schema for
lassification of recommendations and level of evidence is
ummarized in Figure 1, which also illustrates how the grading
ystem provides an estimate of the size of the treatment effect
nd an estimate of the certainty of the treatment effect.
Please note the use of bold-faced type in the recommen-
dations shows where the intent of the recommendation
has changed from the 2002 ACC/AHA Guideline
Update on Perioperative Cardiovascular Evaluation for
Noncardiac Surgery. The bold-faced type only high-
lights changes to the recommendations; it does not show
changes to supporting text, tables, and figures.
The Committee consisted of acknowledged experts in
eneral cardiology as well as persons with recognized
xpertise in more specialized areas including anesthesiology,
ardiovascular surgery, echocardiography, electrophysiology,
nterventional cardiology, nuclear cardiology, vascular med-
cine, and vascular surgery; both academic and private
ectors were represented. The following organizations as-
igned official representatives: the Society for Vascular
edicine and Biology, American Society of Nuclear Car-
iology, Heart Rhythm Society, Society for Vascular Sur-
ery, American Society of Echocardiography, Society of
ardiovascular Anesthesiologists, and the Society for Car-
iovascular Angiography and Interventions.
This document was reviewed by 2 official reviewers
ominated by the ACC; 2 official reviewers nominated by
he AHA; 1 official reviewer from the ACC/AHA Task
orce on Practice Guidelines as well as reviewers from the
ociety for Vascular Medicine and Biology, American Society
able 1. Recommendations for Perioperative Beta-Blocker Thera
Low Cardiac
Patient Risk
ascular Surgery Class IIb
Level of Evidence: C
igh-/Intermediate-Risk
Surgery
‡
ow-Risk Surgery ‡
Applies to patients found to have coronary ischemia on preoperative testing. †Applie
urther discussion.
CHD  coronary heart disease.f Nuclear Cardiology, Heart Rhythm Society, Americanociety of Echocardiography, Society of Cardiovascular
nesthesiologists, and the Society for Cardiovascular An-
iography and Interventions; and 20 content reviewers,
ncluding members from American College of Cardiology
oundation (ACCF) Cardiac Catheterization Committee,
CCF Peripheral Vascular Disease Committee, ACCF
ardiovascular Clinical Imaging Committee, ACCF Echo-
ardiography Committee, ACCF Clinical Electrophysiol-
gy Committee, AHA Council on Cardiopulmonary Peri-
perative and Critical Care Leadership Committee, AHA
ouncil on Cardiovascular Surgery and Anesthesia Leader-
hip Committee, and the AHA Council on Clinical Car-
iology, Electrocardiography, and Arrhythmias Committee.
. PERIOPERATIVE MEDICAL THERAPY
.1. Perioperative Beta-Blocker Therapy
ecommendations for Beta-Blocker Medical Therapy
Table 1):
lass I
. Beta blockers should be continued in patients undergo-
ing surgery who are receiving beta blockers to treat
angina, symptomatic arrhythmias, hypertension, or
other ACC/AHA Class I guideline indications.
(Level of Evidence: C)
. Beta blockers should be given to patients undergoing
vascular surgery at high cardiac risk owing to the finding
of ischemia on preoperative testing. (Level of Evidence: B)
lass IIa
. Beta blockers are probably recommended for patients
undergoing vascular surgery in whom preoperative as-
sessment identifies coronary heart disease. (Level of
Evidence: B)
. Beta blockers are probably recommended for patients
in whom preoperative assessment for vascular surgery
identifies high cardiac risk as defined by the presence
ased on Published Randomized Clinical Trials
Intermediate Cardiac
Patient Risk
CHD or High Cardiac
Patient Risk
Patients found to have myocardial
ischemia on preoperative testing
Class IIb
Level of Evidence: C
Class I*
Level of Evidence: B
Class IIa†
Level of Evidence: B
Class IIb
Level of Evidence: C
Class IIa
Level of Evidence: B
‡ ‡
atients found to have coronary heart disease. ‡Indicates insufficient data. See text forpy B
s to pof multiple clinical risk factors.* (Level of Evidence: B)
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in whom preoperative assessment identifies coronary
heart disease or high cardiac risk as defined by the
presence of multiple clinical risk factors* and who are
undergoing intermediate- or high-risk procedures as
defined in these guidelines. (Level of Evidence: B)
lass IIb
. Beta blockers may be considered for patients who are
undergoing intermediate- or high-risk procedures as
defined in these guidelines, including vascular sur-
gery, in whom preoperative assessment identifies
intermediate cardiac risk as defined by the presence of
a single clinical risk factor.* (Level of Evidence: C)
. Beta blockers may be considered in patients under-
going vascular surgery with low cardiac risk (as
defined in these guidelines) who are not currently on
beta blockers. (Level of Evidence: C)
lass III
. Beta blockers should not be given to patients undergo-
ing surgery who have absolute contraindications to beta
blockade. (Level of Evidence: C)
Please see Table 2, Clinical Predictors of Increased Periop-
able 2. Clinical Predictors of Increased Perioperative
ardiovascular Risk (Myocardial Infarction, Heart Failure,
eath)
ajor
nstable coronary syndromes
Acute or recent MI* with evidence of important ischemic risk by
clinical symptoms or noninvasive study
Unstable or severe† angina (Canadian Class III or IV)‡
ecompensated heart failure
ignificant arrhythmias
High-grade atrioventricular block
Symptomatic ventricular arrhythmias in the presence of underlying
heart disease
Supraventricular arrhythmias with uncontrolled ventricular rate
evere valvular disease
ntermediate
ild angina pectoris (Canadian Class I or II)
revious MI by history or pathological Q waves
ompensated or prior heart failure
iabetes mellitus (particularly insulin-dependent)
enal insufficiency
inor
dvanced age
bnormal ECG (left ventricular hypertrophy, left bundle-branch block,
ST-T abnormalities)
hythm other than sinus (e.g., atrial fibrillation)
ow functional capacity (e.g., inability to climb one flight of stairs with
a bag of groceries)
istory of stroke
ncontrolled systemic hypertension
The American College of Cardiology National Database Library defines recent MI as
reater than 7 days but less than or equal to 1 month (30 days); acute MI is within
days. †May include “stable” angina in patients who are unusually sedentary.
Campeau et al. (2).
ECG  electrocardiogram; MI  myocardial infarction.rative Cardiovascular Risk, for an explanation of the hlinical risk factors. High cardiac risk includes patients with
ajor and intermediate clinical predictors. Care should be
aken in applying recommendations on beta-blocker therapy
o patients with decompensated heart failure, nonischemic
ardiomyopathy, high-degree AV block, or severe valvular
eart disease in the absence of coronary heart disease.
.1.1. Summary of evidence. Despite several meta-
nalyses, some reaching conflicting conclusions, there are
till very few randomized trials of medical therapy before
oncardiac surgery to prevent perioperative cardiac compli-
ations. The studies that have been conducted in this area
ave largely focused on beta-blocker therapy; however, there
emain many limitations to the available data. Few studies
ave compared different beta-blocker agents or character-
zed their dose effect in the perioperative setting. Even fewer
ave included a protocol for the titration of therapy to effect
e.g., target heart rate), or examined regimens that include a
reoperative trial of beta-blocker therapy. Studies to deter-
ine the ideal target population, ideal dose, and route are
acking. In addition, the practical limitations such as how,
hen, how long, and by whom perioperative beta-blocker
herapy is ideally or practically implemented remain unad-
ressed. Randomized, controlled trials are still needed to
xplore the observation that there may be some harm
ssociated with beta-blocker therapy in low-risk patients
3). Moreover, there is currently a lack of data regarding
hich beta blocker to use perioperatively. Some observa-
ional data suggest that perioperative death or myocardial
nfarction (MI) rates may differ when different beta-blockers
re given perioperatively (4). In summary, the best approach
n how to medically protect patients from cardiovascular
omplications during noncardiac surgery is still unknown.
Limitations in the Perioperative Beta-Blocker Literature:
Most trials are inadequately powered.
Few randomized trials of medical therapy to prevent
perioperative major adverse cardiac events have been
performed.
Few randomized trials have examined titration of therapy
to effect (e.g., target heart rate).
Few randomized trials have examined the role of periop-
erative beta-blocker therapy.
Studies to determine the role of beta blockers in
intermediate- and low-risk populations are lacking.
Studies to determine the optimal type of beta blockers are
lacking.
No studies have addressed care-delivery mechanisms in
the perioperative setting, identifying how, when, and by
whom perioperative beta-blocker therapy should be im-
plemented and monitored.
Although many of the randomized, controlled trials of
eta-blocker therapy are small, the weight of evidence—
specially in aggregate—suggests a benefit to perioperative
eta blockade during noncardiac surgery, particularly in
igh-risk patients. Current studies suggest that beta block-
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I and death in high-risk patients. Available evidence
uggests, but does not definitively prove that, when it is
ossible, beta blockers should be started several days or
eeks before elective surgery, with the dose titrated to
chieve a resting heart rate between 50 and 60 beats per
in, to assure that the patient is indeed receiving the benefit
f beta blockade and should continue during the intraoper-
tive and postoperative period to maintain a heart rate less
han 80 beats per min (5). Several prospective, randomized
rials are either underway or soon to be presented. These
ill hopefully shed light on some of the questions regarding
erioperative beta-blocker therapy. Per the ACC/AHA
ask Force on Practice Guidelines methodology, unpub-
ished data cannot be used to formulate guideline
ecommendations.
Two randomized trials examined the effect of periopera-
ive beta blockers on cardiac events surrounding surgery.
oldermans et al. (5) examined the effect of bisoprolol on
atients undergoing vascular surgery and in patients at
igh-risk for perioperative cardiac complications scheduled
or vascular surgery. Of 846 patients with risk factors for
ardiac disease, 173 patients were found to have new
egional wall motion abnormalities (RWMA) on dobut-
mine stress echocardiogram (DSE). Of these patients, 61
ere excluded from further study owing to large areas
greater than or equal to 5 segments) of RWMA on DSE or
ecause they were already taking beta blockers. The remain-
ng 112 high-risk patients were randomized to standard care
r bisoprolol started at least 7 days preoperatively and
itrated to maintain heart rate less than 60 beats per min
reoperatively and less than 80 beats per min intraopera-
ively and postoperatively. The rates of cardiac death (3.4%
s. 17%; p  0.02) and nonfatal MI (0% vs. 17%; p less than
r equal to 0.001) were lower for the bisoprolol versus
lacebo groups, respectively. Importantly, due to the un-
linded design and inclusion of only high-risk patients in
his study, the results cannot be generalized to all patients
ndergoing noncardiac surgery.
Boersma et al. (6) subsequently reanalyzed the total cohort
f 1,351 consecutive patients considered for enrollment in the
forementioned randomized trial of bisoprolol. Forty-five pa-
ients had perioperative cardiac death or nonfatal MI. A total
f 83% of patients had fewer than three clinical risk factors.
mong this subgroup, patients receiving beta blockers had a
ower risk of cardiac complications (0.8% [2 of 263]) than those
ot receiving beta blockers (2.3% [20 of 855]). In patients with
hree or more risk factors (17%), those taking beta blockers
ho had a DSE demonstrating four or fewer segments of new
all-motion abnormalities had a significantly lower incidence
f cardiac complications (2.3% [2 of 86]) compared with those
ot receiving beta-blocker therapy (9.9% [12 of 121]). How-
ver, among the small group of patients with more extensive
schemia on DSE (five or more segments), there was no
ifference in the incidence of cardiac events (4 of 11 for those
aking beta blockers versus 5 of 15 for those not taking beta rlockers). Therefore, beta-blocker therapy was beneficial in all
ut the subset of patients with more extensive ischemia.
evertheless, one must be cautious about inferring a class effect
rom this observation about bisoprolol and treatment protocol.
The Multicenter Study of Perioperative Ischemia research
roup (7,8) reported on 200 patients undergoing general
urgery randomized to a combination of intravenous and
ral atenolol versus placebo for 7 days. Although they found
o difference in perioperative MI or death, they reported
ignificantly fewer episodes of ischemia by Holter monitor-
ng (24% vs. 39%; p  0.03) in the atenolol versus placebo
roups, respectively. They then followed these patients after
ischarge and documented fewer deaths in the atenolol
roup over the subsequent 6 months (1% vs. 10%; p less
han 0.001). It is not clear why such a brief course of therapy
ould exert such a delayed effect, and the study did not
ontrol for other medications given either before or after
urgery. Angiotensin-converting enzyme inhibitor and beta-
locker use preoperatively differed significantly between the
tudy groups.
Additional studies have examined the use of perioperative
eta blockers but are limited in power to detect cardiac events
r are not randomized. Stone et al. (9) randomized a group of
atients with mild hypertension who underwent predomi-
antly (58%) vascular surgery to oral beta blockers 2 h before
urgery or standard care. Control subjects had a higher fre-
uency (28%) of ST-segment depression (on intraoperative
onitoring, as reported by the authors) than treated patients
2%). In a nonrandomized study, Pasternack et al. (10) gave
ral metoprolol immediately before surgery, followed postop-
ratively by intravenous metoprolol during abdominal aortic
neurysm repair. Only 3% suffered an acute MI compared with
8% for matched controls. Pasternack et al. (11) subsequently
eported fewer episodes of intraoperative ischemia in patients
reated with oral metoprolol before peripheral vascular surgery
ompared with untreated patients. Yeager et al. (12) reported a
ase-control analysis of their experience with perioperative MI
uring vascular surgery, comparing 53 index cases of periop-
rative MI with 106 matched controls. They found a strong
ssociation of beta-blocker use with a decreased likelihood of
I (odds ratio  0.43; p  0.01). Raby et al. (13) demon-
trated in 26 vascular surgery patients with documented pre-
perative ischemia and randomized to a protocol of heart rate
uppression with intravenous esmolol compared to standard
are that the esmolol group had fewer episodes of ischemia
han controls (33% vs. 73%; p  0.055). Zaugg et al. (14)
andomized elderly noncardiac surgery patients to preoperative
nd postoperative atenolol titrated to heart rate and intraoper-
tive atenolol titrated to heart rate or no beta blockers, and
etected no episodes of intraoperative myocardial ischemia,
lectrocardiographic changes consistent with MI, or death in
ny group. Three (of 19) patients in the no beta-blocker group
eveloped significant elevations of cardiac troponin-I consis-
ent with a perioperative MI compared with 0 (of 40) patients
ho received one of the atenolol groups. Brady et al. (15)andomized patients undergoing elective vascular surgery to
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dmission to hospital, until 7 days postoperatively. They found
o difference in cardiovascular events, which included MI,
nstable angina, ventricular tachycardia, and stroke. This trial
ay have been underpowered (n 103) to identify a difference
n outcomes, particularly hard outcomes of death and MI.
lso, by trial design, therapy was initiated the day before
ascular surgery, and it is quite possible that those randomized
o metoprolol received incomplete beta blockade in the early
erioperative period.
Perioperative beta-blocker therapy has been reviewed in
everal meta-analyses and in a very large cohort population
tudy. Auerbach and Goldman (16) undertook a review of this
opic in 2002. They reported on a MEDLINE search and
iterature review of only five studies. (All five studies are
ncluded in Table 3.) They calculated a number needed to
reat, on the basis of these studies, of only 2.5 to 6.7 to see
mprovement in measures of myocardial ischemia, and only 3.2
o 8.3 in studies reporting a significant impact of beta blockers
n cardiac or all-cause mortality. They concluded that the
iterature supports a benefit of beta blockers on cardiac
orbidity.
A systematic review of the perioperative medical therapy
iterature by Stevens et al. (17) for noncardiac surgery
ncluded the results of 11 trials using beta blockers for
erioperative therapy. These authors concluded that beta-
lockers significantly decreased ischemic episodes during
nd after surgery. Beta blockers significantly reduced the
isk of nonfatal MI; however, the results became nonsig-
ificant if the two most positive trials were eliminated.
ikewise, the risk of cardiac death was significantly
ecreased with beta-blocker usage. It should be noted
hat these authors incorporated studies not considered in
ther meta-analyses, including studies that were not
linded. Results to be quantified were limited to those in
he 30-day perioperative period. The authors also re-
orted a direct relationship between the prevalence of
rior MI and the magnitude of risk reduction observed
ith beta-blocker therapy, suggesting that higher risk
onfers greater benefit. The number needed to prevent
erioperative ischemia was 8 patients, the number needed
o prevent MI was 23, and 32 subjects must be treated to
revent cardiac death. These authors point out that,
iven the observation that high-risk patients seem to
eceive all the benefit, the target population for beta-
locker therapy is not clear. They also highlighted that
chedules of beta-blocker administration varied signifi-
antly among the reported studies and the potential for a
ingle large strongly positive study to skew the results of
his meta-analysis.
In contrast, Devereaux et al. (18) published their opinion
aper on the clinical evidence regarding the use of beta-
locker therapy in patients undergoing noncardiac surgery
or the purpose of preventing perioperative cardiac compli-
ations. They expressed the opinion that the literature
upporting use of beta blockers during noncardiac surgery is todest at best, based on a few small, unblinded studies with
focused patient population. In a review of the literature in
005, Devereaux et al. (19) discussed 22 studies randomiz-
ng 2,437 patients undergoing noncardiac surgery to beta-
locker therapy or placebo. The POBBLE study was not
ncluded in this review (14). They found no statistically
ignificant benefit on any of the individual outcomes and a
nominally” statistically significant benefit (relative risk of
.44 with 95% confidence interval [CI] 0.20 to 0.97, 99%
I 0.16 to 1.24) for the composite outcome of cardiovas-
ular mortality, nonfatal MI, and nonfatal cardiac arrest.
he authors felt these data were inadequate to draw
onclusions and that a larger, controlled study is indicated
efore conclusions can be made. This review, however,
ncluded a wide variety of studies, patient populations, and
eta-blocker regimens. Many of the studies described only a
ingle or double dose of beta blocker preoperatively or at
nduction of anesthesia. Much of the data, therefore, does
ot pertain to perioperative beta blockade for the purpose of
ardiac risk reduction or focused on a low-risk population.
dditionally, the largest studies included—that is, those
eported by Miller et al. (20) and preliminary data from
ang et al. (21), which together account for almost as many
ubjects as all other studies combined—may not have been
ppropriate to include in this analysis. The first, by Miller et
l. (20), was a study of a single intravenous dose of beta
locker for the purpose of blood pressure control during
ntubation, not reduction of perioperative events. It in-
luded follow-up only to the point of discharge from the
ecovery room. The second, that of Yang et al. (21), has yet
o be published and, therefore, has not undergone formal
eer review. The studies included in this review also vary
idely in length of follow-up.
McGory et al. (22) performed a meta-analysis of six ran-
omized trials of perioperative beta blockade and concluded
hat therapy was associated with significant reductions in
erioperative myocardial ischemia (33% to 15%), MI, cardiac
ortality, and long-term cardiac mortality (12% to 2%). These
uthors used the combined data to derive odds ratios and CIs
or several outcomes. For perioperative overall mortality the
dds ratio for beta-blocker therapy was 0.52 (95% CI 0.20 to
.35), and for perioperative cardiac mortality the odds ratio was
.25 (95% CI 0.07 to 0.87). Neither the POBBLE study nor
he unpublished findings included in the Devereaux et al. (19)
aper were included, explaining the marked difference in
ndings from the other meta-analysis.
A cohort study by Lindenauer et al. (23) reviewed records
rom over 700,000 patients undergoing noncardiac surgery at
29 hospitals in the United States. Participant hospitals in this
ohort study were members of a consortium database measur-
ng quality and health care use. These authors evaluated all
oncardiac surgical cases, and compared those who received
eta blockers within the first 2 days of hospitalization with
hose who did not receive beta blockers during the first 2
ospital days. The authors used propensity score matching
echniques in an attempt to reduce bias. These authors found
Table 3. Randomized Trials of Perioperative Prophylactic Beta Blockers and Cardiac Morbidity
Ischemia* MI Death
Author, Year
(Ref.) Procedure n Control Drug Control Drug Control Drug Control Drug
Stone,
1988 (9)
Noncardiac 128 Placebo Labetalol
Atenolol
Olprenolol
PO preoperatively
11/39 2/89† 0/39 0/89
Mild hypertension (28%) (2%) (0) (0)
Poldermans,
1999 (5)
Vascular 112 Unblinded 5 to 10 mg PO bisoprolol 9/53 0/59† 9/53 2/59†
(17%) (0) (17%) (3%)
Raby,
1999 (13)
Vascular 26 Placebo IV esmolol 8/11 5/15†
(73%) (33%)
Wallace,
1998 (8)
Mangano,
1996 (7)
Noncardiac 200 Placebo 10 to 20 mg IV or 50 to
100 mg PO atenolol
39/101 24/99† (at 6 months)
(39%) (24%) 10/101
(10%)
1/99†
(1%)
Zaugg,
1999 (14)
Noncardiac 63
(59 analyzed)
No perioperative
beta blockers
Atenolol targeted to
maintain HR either
1) pre- and
postoperatively or
2) intraoperatively
0/20 0/43 3/19 0/40
(0%) (0%) (16%) (0%)
Urban,
2000 (25)
Noncardiac 107 Placebo IV esmolol on the day of
surgery, followed by
metoprolol starting at
25 mg PO BID and
increased to maintain a
HR less than 80 beats/
min, and continued for
the next 48 h
8/55 3/52 3/55 1/52
(15%) (6%) (5%) (2%)
Brady,
2005 (15)
Vascular 103 Placebo 50 mg PO metoprolol
twice daily
preoperatively until
7 days post surgery
4/44 5/53 5/44 3/53 1/44 3/53
(9%) (9%) (11%) (6%) (2%) (6%)
*Myocardial ischemia. †p less than 0.05 for drug versus control.
BID  twice per day; HR  heart rate; IV  intravenous; MI  myocardial infarction; PO  by mouth.
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based on the presence of history of ischemic heart disease,
erebrovascular disease, renal insufficiency, diabetes mellitus, or
patient undergoing high-risk surgery), patients who received
eta blockers were significantly less likely to die in hospital.
his was not true for those with a revised risk index of 2, l, or
. Those with a risk index of 0 were more likely to die in
ospital if given a beta blocker on Day 1 or Day 2 of
ospitalization. This study is retrospective and not randomized
nd, therefore, is subject to potential bias. This is particularly
rue in terms of reporting bias, as the documentation was based
ntirely on administrative data sets, using arbitrary definitions
f “on” or “off” perioperative beta blockers, based solely on
ospital day of use. Nonetheless, there appears to be an
ssociation between improved outcomes and the use of beta
lockers in clinically high-risk patients.
Finally, one recent observational cohort study examined the
uestion of which beta blocker may be best for perioperative
edical therapy. Redelmeier et al. (4) reviewed administrative
ata related to elective surgery in Ontario, Canada, and
ocumented perioperative beta-blocker usage from April 1992
o April 2002 (10 years). They limited their analysis to patients
ver the age of 65 years, who were receiving either atenolol or
etoprolol before and after surgery and identified 37,151
ubjects. A total of 1,038 suffered either a perioperative MI or
eath, and the rate of MI or death was significantly lower
mong those patients receiving atenolol versus metoprolol
2.5% vs. 3.2%, p less than 0.001). This difference persisted
ven after adjusting for demographic, clinical, and surgical
actors. The inclusion of other long-acting beta blockers in the
nalysis yielded an identical risk reduction. These data suggest
hat long-acting beta blockade (when therapy is initiated before
urgery) may be superior to short-acting beta blockade. These
bservations await clinical trial evaluation.
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